Chronic Rhinosinusitis Trial, Recruiting (NCT06191640)

Chronic Rhinosinusitis Trial, Recruiting NCT06191640 Sponsor: University of California, Los Angeles Condition: Chronic Rhinosinusitis

Printed from Voxsanity (voxsanity.com.au) — NCT06191640 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Chronic Rhinosinusitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For children who will be starting a highly effective CF medication (HEMT group):

The child has been officially diagnosed with cystic fibrosis (CF)
The child is between 2 and 8 years old at their first study visit
The child has a specific CF gene type that qualifies them for one of two CF medications: ivacaftor or elexacaftor/tezacaftor/ivacaftor (confirm with trial site)
The child's doctor plans to prescribe one of these medications, and the child must join the study before starting it

For children who will NOT be starting a highly effective CF medication (control group):

The child has been officially diagnosed with cystic fibrosis (CF)
The child is between 2 and 8 years old at their first study visit
The child either does not qualify for ivacaftor or elexacaftor/tezacaftor/ivacaftor based on their gene type, or their doctor has decided not to start these medications

Who may not be able to join:

The child has taken part in a study using an experimental drug in the 28 days before their first study visit
The child has taken ivacaftor or elexacaftor/tezacaftor/ivacaftor in the 180 days before their first study visit
The child has been taking oral steroid tablets regularly in the 28 days before their first study visit
The child has had sinus surgery in the 180 days before their first study visit

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel M Beswick, MD, University of California, Los Angeles

Phone: 310-206-8457

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06191640

Sponsor: University of California, Los Angeles

Phase: Not Applicable

Status: Recruiting

Condition: Chronic Rhinosinusitis

Trial contact: 310-206-8457

More information: https://clinicaltrials.gov/study/NCT06191640

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For children who will be starting a highly effective CF medication (HEMT group):

The child has been officially diagnosed with cystic fibrosis (CF)
The child is between 2 and 8 years old at their first study visit
The child has a specific CF gene type that qualifies them for one of two CF medications: ivacaftor or elexacaftor/tezacaftor/ivacaftor (confirm with trial site)
The child's doctor plans to prescribe one of these medications, and the child must join the study before starting it

For children who will NOT be starting a highly effective CF medication (control group):

The child has been officially diagnosed with cystic fibrosis (CF)
The child is between 2 and 8 years old at their first study visit
The child either does not qualify for ivacaftor or elexacaftor/tezacaftor/ivacaftor based on their gene type, or their doctor has decided not to start these medications

Who may not be able to join:

The child has taken part in a study using an experimental drug in the 28 days before their first study visit
The child has taken ivacaftor or elexacaftor/tezacaftor/ivacaftor in the 180 days before their first study visit
The child has been taking oral steroid tablets regularly in the 28 days before their first study visit
The child has had sinus surgery in the 180 days before their first study visit

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of California, Los Angeles

Registry

ClinicalTrials.gov

Start date

12 April 2023

Est. completion

30 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in MRI sinus opacification; Change in olfactory bulb volume

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov